Table 1.

Clinical characteristics and demographics of patients on ECMO

Clinical characteristics	N	Demographics	All	Survivors	Non-survivors	p-value
Diagnosis		Age (years)	14 (1–18)	9 (4–16)	16 (1–18)	0.286
ALL	5	Weight (kg)	47 (7–74)	26 (12–50)	56 (7–74)	0.286
AML	3	Pre ECMO
JMML	1	pH	7.2 (7.0–7.6)	7.3 (7.0–7.6)	7.2 (7.0–7.4)	0.413
Reason for ARF		Lactate (mg/dL)	17 (7–68)	17 (7–24)	17 (8–68)	0.556
Fungal infection	3	pO2/FiO2	47 (32–67)	66 (32–67)	44 (34–50)	0.286
Pulmonary infection^a	4	VIS score	45 (5–160)	11 (5–45)	85 (22–160)	0.032
TRALI	1	Platelet count (× 10³/μL)	27 (14–214)	145 (26–214)	27 (14–53)	0.111
Leukemic infiltration	1	Ventilation days	3 (0.4–14)	4.5 (1–13)	2 (0.4–12)	0.556
Causes of death on ECMO		During ECMO
Intracranial hemorrhage	1	Platelet count (× 10³/μL)	35 (19–106)	98 (22–106)	30 (19–48)	0.041
Multiorgan failure	2	Platelets transfusions / day	2.2 (0.2–3.8)	0.5 (0.2–2.2)	3.3 (1.7–4.7)	0.111
Leukemic infiltration	1	VV Cannulation	7	5	2
Outcome on ECMO		VA Cannulation	2	0	2
Survived on ECMO	5	Major bleeding	4	0	4
Discharged from hospital	4	Need for CRRT	3	0	3
Survived long-term	4	ECMO Duration (days)	14 (2–24)	15 (9–24)	5 (2–17)	0.032

^ano organism detected

ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, JMML juvenile myelomonocytic leukemia, ARF acute respiratory failure, ^ano organism detected, ECMO extracorporeal membrane oxygenation, TRALI transfusion-related acute lung injury, VIS vasoactive inotrope score = dose of dopamine (μg/kg/min) + dose of dobutamine (μg/kg/min) + 100 x dose of adrenaline (μg/kg/min) + 100 x dose of noradrenaline (μg/kg/min) + 10 x milrinone dose (μg/kg/min) + 10,000 x dose of vasopressin (U/kg/min), VV veno-venous, VA veno-arterial, CRRT continuous renal replacement therapy